Redirected tumor-specific allogeneic T cells for universal treatment of cancer

Blood

Volumn 118, Issue 4, 2011, Pages 975-983

  Marcus, Assaf ^a,b   Waks, Tova ^a   Eshhar, Zelig ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; FINGOLIMOD; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ALLOIMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL THERAPY; CONTROLLED STUDY; EX VIVO STUDY; GRAFT VERSUS HOST REACTION; IRRADIATION; LYMPHOCYTE MIGRATION; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR SPECIFIC ALLOGENEIC T CELL THERAPY;

EID: 79960994829     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-334284     Document Type: Article

References (33)

1. Rosenberg SA, Restifo NP, Yang JC, Morgan RA, Dudley ME. Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer. 2008;8(4):299-308. (Pubitemid 351430867)
2. Dudley ME, Wunderlich J, Nishimura MI, et al. Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother. 2001;24(4):363-373. (Pubitemid 32825868)
3. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850-854. (Pubitemid 35231542)
4. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
5. Eshhar Z. The T-body approach: redirecting T cells with antibody specificity. Handb Exp Pharmacol. 2008;181:329-342.
6. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215-223.
7. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170. (Pubitemid 46697905)
8. Appelbaum FR. The current status of hematopoietic cell transplantation. Annu Rev Med. 2003;54:491-512. (Pubitemid 37386409)
9. Dazzi F, Goldman JM. Adoptive immunotherapy following allogeneic bone marrow transplantation. Annu Rev Med. 1998;49:329-340. (Pubitemid 28197458)
10. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
11. Clift RA, Storb R. Histoincompatible bone marrow transplants in humans. Annu Rev Immunol. 1987;5:43-64.
12. Zakrzewski JL, Suh D, Markley JC, et al. Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors. Nat Biotechnol. 2008;26(4):453-461. (Pubitemid 351501816)
13. Boni A, Muranski P, Cassard L, et al. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. 2008;112(12):4746-4754.
14. Cyster JG. Chemokines, sphingosine-1-phosphate, and cell migration in secondary lymphoid organs. Annu Rev Immunol. 2005;23:127-159. (Pubitemid 40563167)
15. Matloubian M, Lo CG, Cinamon G, et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature. 2004;427(6972):355-360. (Pubitemid 38133663)
16. Hashimoto D, Asakura S, Matsuoka K, et al. FTY720 enhances the activation-induced apoptosis of donor T cells and modulates graft-versushost disease. Eur J Immunol. 2007;37(1):271-281. (Pubitemid 46128807)
17. Taylor PA, Ehrhardt MJ, Lees CJ, et al. Insights into the mechanism of FTY720 and compatibility with regulatory T cells for the inhibition of graft-versus-host disease (GVHD). Blood. 2007;110(9):3480-3488. (Pubitemid 350106345)
18. Tedesco-Silva H, Szakaly P, Shoker A, et al. FTY720 versus mycophenolate mofetil in de novo renal transplantation: six-month results of a double-blind study. Transplantation. 2007;84(7):885-892. (Pubitemid 351338950)
19. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med. 2006;355(11):1124-1140. (Pubitemid 44394919)
20. Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720. J Clin Invest. 2003;111(5):659-669. (Pubitemid 36278584)
21. Friedmann-Morvinski D, Bendavid A, Waks T, Schindler D, Eshhar Z. Redirected primary T cells harboring a chimeric receptor require costimulation for their antigen-specific activation. Blood. 2005;105(8):3087-3093.
22. Edinger M, Sweeney TJ, Tucker AA, Olomu AB, Negrin RS, Contag CH. Noninvasive assessment of tumor cell proliferation in animal models. Neoplasia. 1999;1(4):303-310.
23. Pinthus JH, Waks T, Malina V, et al. Adoptive immunotherapy of prostate cancer bone lesions using redirected effector lymphocytes. J Clin Invest. 2004;114(12):1774-1781. (Pubitemid 40385533)
24. Stephan MT, Ponomarev V, Brentjens RJ, et al. T cell-encoded CD80 and 4-1BBL induce autoand transcostimulation, resulting in potent tumor rejection. Nat Med. 2007;13(12):1440-1449. (Pubitemid 350224246)
25. Qiao J, Kottke T, Willmon C, et al. Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med. 2008;14(1):37-44.
26. Dotti G, Savoldo B, Brenner M. Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?" Hum Gene Ther. 2009;20(11):1229-1239.
27. Haque T, Wilkie GM, Jones MM, et al. Allogeneic cytotoxic T-cell therapy for EBV-positive post-transplantation lymphoproliferative disease: results of a phase 2 multicenter clinical trial. Blood. 2007;110(4):1123-1131. (Pubitemid 47281407)
28. Leen AM, Christin A, Myers GD, et al. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation. Blood.2009;114(19):4283-4292.
29. Melenhorst JJ, Leen AM, Bollard CM, et al. Allogeneic virus-specific T cells with HLA alloreactivity do not produce GVHD in human subjects. Blood. 2010;116(22):4700-4702.
30. Amir AL, D'Orsogna LJ, Roelen DL, et al. Allo-HLA reactivity of virus-specific memory T cells is common. Blood. 2010;115(15):3146-3157.
31. Gaston JS, Rickinson AB, Epstein MA. Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants. J Exp Med. 1983;158(6):1804-1821. (Pubitemid 14210789)
32. Bondanza A, Valtolina V, Magnani Z, et al. Suicide gene therapy of graft-versus-host disease induced by central memory human T lymphocytes. Blood. 2006;107(5):1828-1836. (Pubitemid 43289360)
33. Kaneko S, Mastaglio S, Bondanza A, et al. IL-7 and IL-15 allow the generation of suicide gene-modified alloreactive self-renewing central memory human T lymphocytes. Blood. 2009;113(5):1006-1015.